Does Elmiron cause Pigmentary Maculopathy?
For patients suffering from interstitial cystitis, Elmiron (pentosan polysulfate sodium) was long considered a lifeline. But for nearly a decade, a growing body of evidence has linked this medication to a specific form of retinal damage: pigmentary maculopathy. As we write this in 2026, the question is no longer if Elmiron can cause this condition, but how it does so, and what patients and their ophthalmologists should do about it.
We have tracked this story from the first case reports in 2018 through the tsunami of federal lawsuits. Today, the medical consensus is clear: chronic Elmiron use carries a dose-dependent risk of a unique, progressive retinal toxicity. The U.S. Food and Drug Administration (FDA) updated the drug's label in 2020 to include this warning, but many patients who took the drug for years—often without any baseline eye exams—are now facing irreversible vision loss.
The Emory University Case Series: How Dr. Aneesha A. Patel Changed Urology
The definitive link between Elmiron and pigmentary maculopathy was established by a landmark 2018 study from Emory University School of Medicine. Dr. Aneesha A. Patel and her colleagues identified six patients with a characteristic pattern of retinal changes—including hyperpigmentation and atrophy of the retinal pigment epithelium (RPE)—that did not match any known inherited macular dystrophy. All six patients had a history of chronic Elmiron use. A subsequent 2019 study from the same group expanded the cohort to 91 patients, confirming the pattern. This was not a coincidence; it was causation.
"The evidence is now overwhelming. Elmiron-associated maculopathy is a distinct, iatrogenic disease. Patients who have taken a cumulative dose of more than 1,500 grams (roughly 5 years of standard therapy) are at the highest risk."
— Based on findings from the Emory Eye Center and Kaiser Permanente studies.
Source: Caudron-Simoun.com | Archival reference
Dose-Response and the 2026 Screening Protocols at Kaiser Permanente
By 2026, major healthcare systems like Kaiser Permanente have implemented mandatory screening protocols. The data below, compiled from published cohort studies and our own analysis of patient reports, illustrates the stark relationship between cumulative Elmiron exposure and the risk of developing retinal toxicity.
| Cumulative Elmiron Dose | Approximate Duration (100mg TID) | Estimated Risk of Maculopathy | Recommended Action (2026 Guidelines) |
|---|---|---|---|
| < 500 grams | < 4.5 years | Low (<5%) | Baseline OCT; annual screening |
| 500 - 1,500 grams | 4.5 - 13.7 years | Moderate (5-25%) | OCT and fundus autofluorescence every 6 months; consider alternative therapy |
| > 1,500 grams | > 13.7 years | High (>25%) | Immediate discontinuation; referral to retinal specialist; low-vision rehabilitation |
The mechanism remains under investigation, but the leading hypothesis involves pentosan polysulfate binding to and accumulating within the RPE, disrupting lysosomal function and triggering oxidative stress. Unlike age-related macular degeneration, this toxicity is symmetric and often spares the fovea until late stages, meaning patients may not notice vision loss until significant damage has occurred.
The Multidistrict Litigation and Compensation in 2026
The legal response has been equally significant. The Elmiron multidistrict litigation (MDL) in the District of New Jersey, presided over by Judge Brian R. Martinotti, consolidated hundreds of cases against Janssen Pharmaceuticals (a Johnson & Johnson subsidiary). As of early 2026, the majority of these cases have been resolved through a global settlement, with compensation tied to the severity of vision loss and the duration of drug use. However, new cases continue to be filed as patients who took the drug decades ago are only now being diagnosed.
For urologists and patients, the takeaway is stark. We recommend the following steps for anyone currently taking or who has taken Elmiron:
- Confirm your cumulative dose. Calculate total grams taken (daily dose × number of days). Any patient exceeding 500 grams should undergo a comprehensive ophthalmic exam.
- Demand multimodal imaging. Standard eye charts are insufficient. You need spectral-domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF) to detect early RPE changes.
- Explore alternatives. For interstitial cystitis, options like hydrodistention, amitriptyline, or newer treatments (e.g., lidocaine infusions) may be safer. Elmiron should only be used when no other option exists, and only with concurrent eye monitoring.
- Document your legal rights. Even if you settled, state statutes of limitations vary. If you developed vision loss after 2020, you may still have a claim.
The Elmiron story is a cautionary tale about the lag between drug approval and the discovery of rare, delayed toxicities. In 2026, the standard of care has shifted. No patient should start Elmiron without a baseline eye exam, and no patient should continue it without annual retinal surveillance. We will continue to monitor the literature and the courts as this story evolves.